Key result
The PRAIS2 risk model demonstrated excellent discrimination and good calibration for predicting 30-day mortality in pediatric patients undergoing cardiac surgery.
Why the study?
Risk stratification in paediatric patients undergoing heart surgery remains a challenge, and the generalisability and clinical utility of the newly developed PRAIS2 risk model required independent temporal external validation.
Does the PRAIS2 risk model accurately predict 30-day mortality in pediatric patients undergoing cardiac surgery?
Observational (n=2,027)
No
Does the PRAIS2 risk model accurately predict 30-day mortality in pediatric patients undergoing cardiac surgery?
The PRAIS2 risk model demonstrates excellent discrimination and good calibration for predicting 30-day mortality in pediatric cardiac surgery, supporting its wider clinical adoption.
Answers are grounded in this paper and cite their sources.
May support preoperative counseling in pediatric cardiac surgery; leaves open prospective validation before routine adoption.
Objective Risk stratification in paediatric patients undergoing heart surgery remains a challenge. The improving partial risk adjustment in surgery (PRAIS2) is a risk model predicting 30-day mortality which has been recently developed and validated using a UK-based cohort from April 2009-March 2015. We aimed to perform an independent temporal external validation to explore its generalisability and clinical utility. Methods PRAIS2 validation was carried out using a single centre (Bristol, UK) cohort from April 2004 to March 2009 and April 2015 to July 2019. For each subject PRAIS2 score was calculated according to the original formula. PRAIS2 performance was assessed in terms of discrimination by means of ROC curve analysis and calibration by using the calibration belt method. Results A total of 1330 (2004-2009) and 1187 (2015-2019) paediatric cardiac surgical procedures were included in the first and second independent validation, respectively (median age at the procedure 6.0 and 6.9 months). PRAIS2 score showed excellent discrimination for both independent validations (AUC 0.72 (95%CI: 0.65 to 0.80) and 0.87 (95%CI: 0.82 to 0.93), respectively). While PRAIS2 was only marginally calibrated in the first validation, with a tendency to underestimate risk P-value = 0.051), the second validation showed good calibration with 95% confidence belt containing the bisector for predicted mortality (P-value = 0.15); We also observed good performance in the subgroup of patients undergoing non-elective procedures (N = 482; AUC 0.78 (95%CI 0.68 to 0.87); Calibration belt containing the bisector (P-value=0.61). Conclusions In a single centre UK-based cohort, PRAIS2 showed excellent discrimination and calibration in predicting 30-day mortality in paediatric cardiac surgery including in those undergoing non-elective procedures. Our results support a wider adoption of PRAIS2 score in the clinical practice. Strengths and limitations of this study A strength of the present study is that data were prospectively collected as part of the UK National Congenital Heart Disease Audit and as such they undergo continuous and inclusive systematic validation that includes the review of a sample of case notes by external auditors to ensure coding accuracy. We used a recently proposed method (calibration belt) which does not require patients to be categorised according to risk percentile but rather provides a risk function across all risk value with relative uncertainty measure (95% CI) A key limitation of this study is that the sample size is relatively small and considerably smaller than the cohort used to develop PRAIS2 Key questions What is already known about this subject? The improving partial risk adjustment in surgery (PRAIS2) is a risk model predicting 30-day mortality which has been recently developed and validated using a UK-wide cohort. What does this study add? The present study reported the first independent external validation of the PRAIS2 using a single centre cohort which confirmed excellent performance of the model and for the first time showed that it also accurately predicts mortality in patients undergoing non-elective procedures How might this impact on clinical practice? Our results support a wider adoption of the PRAIS2 in the clinical practice.
No takes yet. Share an insight, caveat, or question.
Cocomello et al. (2020) conducted an observational in Congenital heart disease (n=2,027). PRAIS2 risk model was evaluated on 30-day mortality discrimination (AUC) in the 2015-2019 validation cohort (AUC 0.87, 95% CI 0.82 to 0.93). The PRAIS2 risk model demonstrated excellent discrimination and good calibration for predicting 30-day mortality in pediatric patients undergoing cardiac surgery.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: